Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Challenges of Accurate Diagnosis of TA-TMA After Hematopoietic Stem Cell Transplant

April 8th 2021

A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.

Novel Agents Expand MDS Treatment Armamentarium After Years of Inactivity

April 8th 2021

Amit K. Verma, MD, spotlights new agents that have entered the myelodysplastic syndrome treatment arsenal and novel combinations currently under exploration, as well as efforts that are showing promise in patients with acute myeloid leukemia.

Relationship Between TA-TMA Development and GVHD

April 8th 2021

The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).

Weight-Based Dosing With Narsoplimab Is Recommended in HSCT-TMA

April 7th 2021

Pharmacodynamic and pharmacokinetic modeling of the investigational MASP-2 inhibitor narsoplimab supported a weight-based dosing method for patients with hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Selinexor, Bortezomib, and Dexamethasone Combination Proves Effective for Myeloma

April 7th 2021

In December 2020, the FDA approved selinexor in combination with the proteasome inhibitor bortezomib and dexamethasone for patients with MM who have received at least 1 prior therapy.

A Review of Pacritinib and PACIFICA Data

April 7th 2021

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Mitigating Peripheral Neuropathy Is Still Focus of Ongoing Research in Hodgkin Lymphoma

April 7th 2021

Mendel Goldfinger, MD, discusses some of the key points of the ECHELON-1 trial data.

Using Second-Generation FLT3 Inhibitors in R/R AML

April 7th 2021

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

Testing for FLT3 During Relapse in AML

April 7th 2021

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

The Role of Transplant in Myelofibrosis

April 7th 2021

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis.

Searching for Molecular Targets in Myeloid Malignancies and Beyond

April 6th 2021

Ulrich Steidl, MD, PhD, discusses translational research efforts that have been made with targeting leukemia stem cells and ongoing clinical trials that are examining novel therapeutic targets in myeloid malignancies and beyond.

D-VCd Rises as the New Standard of Care in Newly Diagnosed AL Amyloidosis

April 6th 2021

Jonathan L. Kaufman, MD, discusses the significance of subcutaneous D-VCd in the treatment of patients with AL amyloidosis, remaining questions with the approach, and emerging strategies for those with high-risk cardiac features.

Genomic Sequencing Identifies Pediatric Therapy-Related Myeloid Neoplasm Defining Variants Prior to Clinical Presentation

April 5th 2021

Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).

Emerging Therapies for R/R Follicular Lymphoma

April 5th 2021

An overview of novel therapies under investigation for the treatment of relapsed/refractory follicular lymphoma and special considerations regarding treating patients with newer, novel agents in the community setting.

Narsoplimab Inhibits C5b-9 and Thrombus Formation in HSCT/BMT-TMA

April 2nd 2021

The addition of narsoplimab to human serum significantly inhibited the formation of C5b-9 and platelet thrombi on human microvascular endothelial cells in 3 patients with acute hematopoietic stem cell transplant – or bone marrow transplant –associated thrombotic microangiopathy.

Simplified Geriatric Assessment Validated as OS Predictor in Elderly Patients With DLBCL

April 2nd 2021

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.

Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML

April 2nd 2021

The multitumor-associated antigen-specific T-cell product MT-401 is under investigation as a potential treatment option for patients with acute myeloid leukemia following allogeneic stem cell transplant in both the adjuvant and active disease settings.

OncLive® Takes a Look Back at Most Listened Podcasts of 2020

April 1st 2021

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Orca-T Offers an Alternative to HSCT With Improved Patient Experience

April 1st 2021

Mehrdad Abedi, MD, discusses the challenges of standard transplant, how Orca-T could overcome some of those limitations, and the potential future of transplant in hematologic malignancies.